OctoPlus (AEX:OCTO)

http://www.fiercebiotech.com/press-releases/enanta-enters-strategic-collaboration-advance-ns5a-inhibitor-candidate-hcv

[quote alias=peebee id=6124993 date=201202162110] [...] Ach, die 8 miljoen aandelen van oktober zijn snel geplaatst, dus de kopers van die aandelen hadden iig nog volop vertrouwen in het aandeel... ben benieuwd naar morgen [/quote]maar de verwatering gaat op deze manier wel erg snel om de 5 maanden een emissie dat kan gewoon niet want dan komt het pharming scenario om de hoek ...... die zijn van 50 miljoen naar 850 miljoen aandelen gegaan in zeer korte tijd en de belegger die mag het betalen !!!!!!

Nog 2 dagen en dan weten we wat Octoplus in 2011 heeft gepresteerd. De recent gescoorde opdrachten hebben allen een "significante" bijdrage in de omzet voor 2012, dus hier valt in 2011 weinig van te verwachten. Contracten eerder in het jaar (bvb:deens groot contract)daar ga ik vanuit dat die een grote bijdrage in omzet 2011 hebben gehad, dus qua omzet zal er ongeveer hetzelfde als in 2010 uitkomen (geen milestones meegenomen) resultaatsverbetering t.o.v. 2011 moet mijn inziens komen van kostenbesparingen en wat dat betreft was Octoplus in de eerste helft van 2011 goed op weg. Echter: in de 2e helft zijn er weer aardig wat mensen aangenomen, en dus minder kostenbesparingen qua loonkosten. de hoop is dat deze mensen volop direct hebben bijgedragen aan de omzet. Ik ga uit van een lichte verbetering van het resultaat tov 2010. En hopelijk mag Octoplus iets meer vertellen omtrent Locteron, aandeelhouders snakken naar info hierover!

samenvoegen.... [Posted 02/09/2012] ISSUE: FDA notified healthcare professionals and patients that drug interactions between the hepatitis C virus (HCV) protease inhibitor Victrelis (boceprevir) and certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these medicines when they are used together. A drug interaction study showed that taking boceprevir (Victrelis) with ritonavir (Norvir) in combination with atazanavir (Reyataz) or darunavir (Prezista), or with Kaletra (lopinavir/ritonavir) reduced the blood levels of the HIV medicines and boceprevir in the body (see Data Summary below). FDA will be updating the Victrelis drug label to include information about these drug interactions. BACKGROUND: Victrelis is a hepatitis C virus (HCV) protease inhibitor used with the medicines pegiBACKGROUND: Victrelis is a hepatitis C virus (HCV) protease inhibitor used with the medicines peginterferon alfa and ribavirin to treat chronic (long-lasting) hepatitis C infection in adults. HIV protease inhibitors are a class of anti-viral drugs used to treat HIV infection. Ritonavir is an HIV protease inhibitor used to “boost” other HIV protease inhibitors, increasing their levels in the blood and making them more effective. RECOMMENDATION: Patients should not stop taking any of their medicines without talking to their healthcare professional. Patients should contact their healthcare professional if they have any questions or concerns. Healthcare professionals who have started patients infected with both chronic HCV and HIV on Victrelis and antiretroviral therapy containing a ritonavir-boosted protease inhibitor should closely monitor patients for HCV treatment response and for potential HCV and HIV virologic rebound. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: nterferon alfa and ribavirin to treat chronic (long-lasting) hepatitis C infection in adults. HIV protease inhibitors are a class of anti-viral drugs used to treat HIV infection. Ritonavir is an HIV protease inhibitor used to “boost” other HIV protease inhibitors, increasing their levels in the blood and making them more effective.

[quote alias=+ id=6096903 date=201202042025] Las laatst een keer(kan het niet vinden ) dat Biolex krap bij kas zat. Nu hebben ze een paar weken terug geld opgehaald t.b.v. SEC-Filling. Investeerders geven/gaven 10milj. Doe er wat mee dan!!! http://www.biolex.com/products-.htm http://apps.firstrain.com/SeekingAlpha/001/dynamic/frlite.do?token=C:BiolexTherapeuticsInc&view=companystandalone&user_id=__fr__user_id_fr__&key=__fr__key__fr__ [/quote] Krap bij kas zit Biolex imho nog steeds. 10 mil. tbv de toezichthouder, amai….. 5.9 van een paar weken terug is iets langer geleden(06-2011) en van de aangeboden 3.2 is 2.4 "verpatst". http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001407698&owner=exclude&count=40 http://www.sec.gov/answers/rule506.htm Clarus Ventures-backed Biolex Therapeutics Raises 75% of $3.2M Offering Biolex Therapeutics Inc. has raised $2.4 million, or 75 percent of a $3.2 million debt offering, from 10 investors, according to an SEC filing. Principals named in the filing by the Pittsboro, N.C.-based drug developer are: • Chairman P. Sheriff Neff; • Executive Chairman Kurt Graves; • President and CEO Jan Turek; • COO David Spencer; • CFO Dale Sander; • Director Dennis Dougherty of Durham, N.C.-based Intersouth Partners; • Director W. Amick, an advisor to Intersouth Partners and Philadelphia-based Quaker BioVentures; • Jeffrey Leiden of Cambridge, Mass.-based Clarus Ventures; • Director David Castaldi, an entrepreneur and former president of Baxter International; and • Liza Nelson of Sweden's Investor Growth Capital with offices in New York. In June, the company raised $5.9 million through a sale of debt and convertible securities. Biolex Therapeutics is a clinical-stage biopharmaceutical company that uses its patented LEX System to develop follow-on biologics, hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a novel technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates.